对不同严重程度得分进行比较,以将血红蛋白水平与肝脏衰竭严重程度相关联:一项观察性研究
Himayat Ullah1, Sarwat Huma2, Ghulam Yasin3
1Department of Medicine, College of Medicine at Shaqra, Shaqra University, Shaqra 15526, Saudi Arabia.
World journal of hepatology
|January 28, 2025
概括
较低的血红蛋白水平与不补偿性肝病患者的严重程度增加有关. 末期肝病模型 (MELD) 评分显示了最强的关联,有助于患者管理和预后.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内部医学 内部医学
- 临床生物化学 临床生物化学
背景情况:
- 慢性肝病是一个日益严重的全球健康挑战,导致肝脏不补偿.
- 贫血在肝硬化中很常见,并且与较差的结果有关.
- 很少有研究研究了血红蛋白水平与肝病严重程度之间的联系.
研究的目的:
- 确定血红蛋白水平与脱补偿性肝病的严重程度之间的关系.
- 为了比较血红蛋白与Child-Pugh,MELD和MELD-Na得分的相关性强度.
主要方法:
- 一项对652名肝病患者进行的横截面研究.
- 收集的人口,临床和实验室数据,包括血红蛋白和严重程度得分 (Child-Pugh,MELD,MELD-Na).
- 斯皮尔曼相关系数评估了血红蛋白和严重程度得分之间的关系.
主要成果:
- 在血红蛋白水平和Child-Pugh,MELD和MELD-Na得分之间观察到显著的逆相关性 (P <0.01).
- 梅尔德得分显示,与血红蛋白水平的相关性最强.
- 在所有评分系统中,血红蛋白水平在严重程度组之间有显著差异 (P = 0.001).
结论:
- 血红蛋白水平与肝脏疾病的严重程度相反相关.
- 在这个人群中,MELD评分是血红蛋白水平的最强相关值.
- 了解这种相关性可以提高患者的预后评估和治疗策略.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
01:24Cirrhosis II: Pathophysiology
53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53
01:29Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71